45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
179,999
Insurances with rates
32
CPT / HCPCS codes
5,987
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| PX-025005727 | HC-Lyfgenia(Lovotibeglogene Autotemcel) Peds per Treatment | $12,059,000 | $4,823,600 | — | — | 8 |
| PX-025005727 | HC-Lyfgenia(Lovotibeglogene Autotemcel) Peds per Treatment | $12,059,000 | $4,823,600 | — | — | 9 |
| PX-025005716 | HC-Zynteglo(Betibeglogene Autotemcel)per Treatment Gene Therapy | $10,900,000 | $4,360,000 | — | — | 8 |
| PX-025005716 | HC-Zynteglo(Betibeglogene Autotemcel)per Treatment Gene Therapy | $10,900,000 | $4,360,000 | — | — | 9 |
| PX-025005726 | HC-Casgevy(Exagamglogene Autotemcel) Peds per Treatment | $8,558,000 | $3,423,200 | — | — | 8 |
| PX-025005726 | HC-Casgevy(Exagamglogene Autotemcel) Peds per Treatment | $8,558,000 | $3,423,200 | — | — | 9 |
| RX-197908 | ONASEMNOGENE ABEPARVOVEC-XIOI 2 X 10EXP13 VG/ML IV SUSPENSION,KIT | $6,278,227 | $2,511,291 | — | — | 8 |
| RX-197908 | ONASEMNOGENE ABEPARVOVEC-XIOI 2 X 10EXP13 VG/ML IV SUSPENSION,KIT | $6,278,227 | $2,511,291 | — | — | 9 |
| PX-025005732 | HC-Tecelra(Afamitresgene Autoleucel) Adults per Therapeutic Dose | $4,180,250 | $1,672,100 | — | — | 8 |
| PX-025005732 | HC-Tecelra(Afamitresgene Autoleucel) Adults per Therapeutic Dose | $4,180,250 | $1,672,100 | — | — | 9 |
| PX-025005501 | HC-Kymriah(Tisagenlecleucel-Car POS-T) Peds | $3,413,000 | $1,365,200 | — | — | 8 |
| PX-025005501 | HC-Kymriah(Tisagenlecleucel-Car POS-T) Peds | $3,413,000 | $1,365,200 | — | — | 9 |
| PX-025005696 | HC-Carvykti(Ciltacabtagene Autoleucel)Car-T Adults 30 Ml | $3,193,035 | $1,277,214 | — | — | 8 |
| PX-025005696 | HC-Carvykti(Ciltacabtagene Autoleucel)Car-T Adults 30 Ml | $3,193,035 | $1,277,214 | — | — | 9 |
| PX-025005700 | HC-Carvykti(Ciltacabtagene Autoleucel)Car-T Adults 70 Ml | $3,193,035 | $1,277,214 | — | — | 8 |
| PX-025005700 | HC-Carvykti(Ciltacabtagene Autoleucel)Car-T Adults 70 Ml | $3,193,035 | $1,277,214 | — | — | 9 |
| PX-025005606 | HC-Breyanzi(Lisocabtagene Maraleucel) Adults | $3,055,000 | $1,222,000 | — | — | 8 |
| PX-025005606 | HC-Breyanzi(Lisocabtagene Maraleucel) Adults | $3,055,000 | $1,222,000 | — | — | 9 |
| PX-025005610 | HC-Breyanzi(Lisocabtagene Maraleucel) Peds | $3,055,000 | $1,222,000 | — | — | 8 |
| PX-025005610 | HC-Breyanzi(Lisocabtagene Maraleucel) Peds | $3,055,000 | $1,222,000 | — | — | 9 |
| PX-025005612 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 250ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 8 |
| PX-025005612 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 250ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 9 |
| PX-025005702 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 500ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 8 |
| PX-025005702 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 500ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 9 |
| PX-025005611 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 50ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 8 |
| PX-025005611 | HC-Abecma(Idecabtagene Vicleucel) Adults (Cart) 50ml Infusion Bag | $3,038,000 | $1,215,200 | — | — | 9 |
| PX-025005734 | HC-Aucatzyl(Obecabtagene Autoleucel)Adults per Infusion | $3,018,750 | $1,207,500 | — | — | 8 |
| PX-025005734 | HC-Aucatzyl(Obecabtagene Autoleucel)Adults per Infusion | $3,018,750 | $1,207,500 | — | — | 9 |
| PX-025005713 | HC-Omisirge (Omidubicel-Onlv) per Dose | $2,944,403 | $1,177,761 | — | — | 8 |
| PX-025005713 | HC-Omisirge (Omidubicel-Onlv) per Dose | $2,944,403 | $1,177,761 | — | — | 39 |
| PX-025005451 | HC-Yescarta(Axicabtagene Ciloleucel) Adults | $2,895,585 | $1,158,234 | — | — | 8 |
| PX-025005451 | HC-Yescarta(Axicabtagene Ciloleucel) Adults | $2,895,585 | $1,158,234 | — | — | 9 |
| PX-025005452 | HC-Yescarta(Axicabtagene Ciloleucel) Peds | $2,895,585 | $1,158,234 | — | — | 8 |
| PX-025005452 | HC-Yescarta(Axicabtagene Ciloleucel) Peds | $2,895,585 | $1,158,234 | — | — | 9 |
| PX-025005502 | HC-Kymriah(Tisagenlecleucel-Dlbcl-6m) Adults | $2,811,000 | $1,124,400 | — | — | 8 |
| PX-025005502 | HC-Kymriah(Tisagenlecleucel-Dlbcl-6m) Adults | $2,811,000 | $1,124,400 | — | — | 9 |
| PX-025005608 | HC-Tecartus (Brexucabtagene Autoleucel)Adults per Ther Dose | $2,657,000 | $1,062,800 | — | — | 8 |
| PX-025005608 | HC-Tecartus (Brexucabtagene Autoleucel)Adults per Ther Dose | $2,657,000 | $1,062,800 | — | — | 9 |
| PX-025005609 | HC-Tecartus (Brexucabtagene Autoleucel)Peds per Ther Dose | $2,657,000 | $1,062,800 | — | — | 8 |
| PX-025005609 | HC-Tecartus (Brexucabtagene Autoleucel)Peds per Ther Dose | $2,657,000 | $1,062,800 | — | — | 9 |
| RX-192499 | VORETIGENE NEPARVOVEC-RZYL 1.5X10EXP11 VG/0.3 ML(FINAL)SUBRETINAL SUSP | $1,142,188 | $456,875 | — | — | 8 |
| RX-192499 | VORETIGENE NEPARVOVEC-RZYL 1.5X10EXP11 VG/0.3 ML(FINAL)SUBRETINAL SUSP | $1,142,188 | $456,875 | — | — | 9 |
| PX-027401212 | HC-Luke Arm Shoulder Configuration | $430,231 | $172,092 | — | — | 8 |
| PX-027401212 | HC-Luke Arm Shoulder Configuration | $430,231 | $172,092 | — | — | 19 |
| PX-081500009 | HC-I-Ubmt-Total Marrow Incl Courier | $417,775 | $167,110 | — | — | 8 |
| PX-081500009 | HC-I-Ubmt-Total Marrow Incl Courier | $417,775 | $167,110 | — | — | 9 |
| PX-081500008 | HC-I-Ubmt-Total Pbsc Incl Courier & Cryopreservation | $406,123 | $162,449 | — | — | 8 |
| PX-081500008 | HC-I-Ubmt-Total Pbsc Incl Courier & Cryopreservation | $406,123 | $162,449 | — | — | 9 |
| RX-188102 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION | $355,095 | $142,038 | — | — | 8 |
| RX-188102 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION | $355,095 | $142,038 | — | — | 9 |
Showing top 50 of 179,999 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.